Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
NCT04588987
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Neoadjuvant Therapy
Carilizumab
Apatinib
Recurrent High-Grade Glioma
Interventions
BIOLOGICAL:
PD-1
Sponsor
Sun Yat-sen University